Mantle Cell Lymphoma | Tumor

Treatment Intensity After Deferring Initial Therapy May Not Indicate Improved Survival in Mantle Cell Lymphoma

May 28th 2021, 1:00pm


Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.

Tecartus May Contribute to Long-Term Responses in Relapsed/Refractory Mantle Cell Lymphoma

May 5th 2021, 1:00pm


Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.

Keep Inspiring

April 28th 2021, 12:30pm


Don’t let your disease define you

Your Previously Treated Mantle Cell Lymphoma (MCL)

April 28th 2021, 12:15pm


Navigating life with blood cancer

First-Line Immunochemotherapy With Maintenance Therapy May Lead to Long-Term Remission in Mantle Cell Lymphoma

April 9th 2021, 9:00pm


A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.

Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma

April 8th 2021, 9:00pm


Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.

Patients With Previously Treated Multiple B-Cell Malignancies Respond Safely to Next-Generation BTK Inhibitor

April 6th 2021, 1:00pm


Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.

Sponsored Content: Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

March 17th 2021, 12:00pm


An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Minimal Residual Disease Positivity After Treatment Could Lead to Worse Outcomes in MCL

February 16th 2021, 10:00pm


A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.

The Top 5 News and Updates in Mantle Cell Lymphoma That Patients May Have Missed in 2020

December 29th 2020, 7:00pm


A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.